• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer.周围型临床 N0 小细胞肺癌(≤2cm)隐匿性支气管周围 N1 淋巴结转移的发生率。
Ann Thorac Surg. 2020 Jan;109(1):270-276. doi: 10.1016/j.athoracsur.2019.07.037. Epub 2019 Aug 31.
2
Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy.PET/CT在临床I期(T1-2aN0)非小细胞肺癌立体定向体部放疗前分期中检测隐匿性N1转移的局限性
Technol Cancer Res Treat. 2017 Feb;16(1):15-21. doi: 10.1177/1533034615624045. Epub 2016 Jun 23.
3
Mandatory Nodal Evaluation During Resection of Clinical T1a Non-Small Cell Lung Cancers.临床T1a期非小细胞肺癌切除术中的强制性淋巴结评估
Ann Thorac Surg. 2022 May;113(5):1583-1590. doi: 10.1016/j.athoracsur.2021.06.078. Epub 2021 Aug 3.
4
Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.肺癌中N1和N2站之间的边界:下叶肿瘤淋巴结转移模式的经验教训
J Thorac Cardiovasc Surg. 2005 Apr;129(4):825-30. doi: 10.1016/j.jtcvs.2004.06.016.
5
Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.外周临床T1a N0期非小细胞肺癌淋巴结转移的临床预测因素
Ann Thorac Surg. 2017 Oct;104(4):1153-1158. doi: 10.1016/j.athoracsur.2017.02.074. Epub 2017 May 24.
6
The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.在肺部炎症性疾病患病率较高的地区,18F-氟脱氧葡萄糖正电子发射断层显像(FDG PET)成像在非小细胞肺癌术前分期中区分N0或N1期与N2期的附加价值。
Clin Nucl Med. 2007 Aug;32(8):607-12. doi: 10.1097/RLU.0b013e3180a1ac87.
7
Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer.cN0 期非小细胞肺癌中最大标准化摄取值与隐匿性纵隔淋巴结转移的相关性
Eur J Cardiothorac Surg. 2016 Nov;50(5):914-919. doi: 10.1093/ejcts/ezw109. Epub 2016 Apr 24.
8
Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less.浸润性成分大小为 3cm 或更小的外周型非小细胞肺癌隐匿性淋巴结转移的危险因素。
World J Surg. 2020 May;44(5):1658-1665. doi: 10.1007/s00268-019-05365-5.
9
Does anatomical segmentectomy allow an adequate lymph node staging for cT1a non-small cell lung cancer?解剖性节段切除术是否能为 cT1a 非小细胞肺癌提供充分的淋巴结分期?
J Thorac Oncol. 2011 Sep;6(9):1537-41. doi: 10.1097/JTO.0b013e3182209063.
10
The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.氟脱氧葡萄糖正电子发射断层扫描原发性肿瘤的最大标准化摄取值是临床 N0 非小细胞肺癌病理性淋巴结受累的良好预测指标。
Eur J Cardiothorac Surg. 2013 Jul;44(1):83-7. doi: 10.1093/ejcts/ezs604. Epub 2012 Dec 11.

引用本文的文献

1
Predicting lymph node metastasis of clinical T1 non-small cell lung cancer: a brief review of possible methodologies and controversies.预测临床T1期非小细胞肺癌的淋巴结转移:对可能方法及争议的简要综述
Front Oncol. 2024 Dec 9;14:1422623. doi: 10.3389/fonc.2024.1422623. eCollection 2024.
2
Standardized intrapulmonary lymph node dissection in lung cancer specimens: A national Colombian analysis.肺癌标本中标准化肺内淋巴结清扫术:一项哥伦比亚全国性分析。
JTCVS Open. 2024 Jun 18;20:174-182. doi: 10.1016/j.xjon.2024.06.004. eCollection 2024 Aug.
3
Is tumor diameter a risk factor for occult N1 metastasis in patients with peripheral non-small cell lung cancer which is smaller than 3 cm?肿瘤直径是否为直径小于3 cm的周围型非小细胞肺癌患者发生隐匿性N1转移的危险因素?
Updates Surg. 2023 Dec;75(8):2335-2342. doi: 10.1007/s13304-023-01575-8. Epub 2023 Jun 29.
4
Nomograms for intraoperative prediction of lymph node metastasis in clinical stage IA lung adenocarcinoma.临床ⅠA 期肺腺癌淋巴结转移术中预测的列线图。
Cancer Med. 2023 Jul;12(13):14360-14374. doi: 10.1002/cam4.6115. Epub 2023 May 22.
5
Characterization of TIM-3 Expression and Its Correlation with TNF- and IFN- in Patients with Surgically Resected Lung Adenocarcinoma.检测 TIM-3 表达特征及其与 TNF-α 和 IFN-γ 在手术切除肺腺癌患者中的相关性。
Dis Markers. 2023 Feb 21;2023:2352945. doi: 10.1155/2023/2352945. eCollection 2023.
6
Analysis of prognostic factors in pT1-2 N1 lung cancer patients in the light surgical results.根据手术结果分析 pT1-2N1 期肺癌患者的预后因素。
Updates Surg. 2023 Jun;75(4):1011-1017. doi: 10.1007/s13304-023-01473-z. Epub 2023 Feb 25.
7
Lymph node metastases outside tumor-bearing lobes and/or segments in non-small cell lung cancer.非小细胞肺癌中肿瘤所在肺叶和/或肺段以外的淋巴结转移
Front Med (Lausanne). 2022 Aug 30;9:960689. doi: 10.3389/fmed.2022.960689. eCollection 2022.
8
Rationale for Combing Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors in Medically Inoperable Early-Stage Non-Small Cell Lung Cancer.立体定向体部放射治疗联合免疫检查点抑制剂用于医学上无法手术的早期非小细胞肺癌的理论依据。
Cancers (Basel). 2022 Jun 27;14(13):3144. doi: 10.3390/cancers14133144.
9
Prognostic implication of isolated pulmonary nodules in patients with a history of breast cancer.孤立性肺结节对乳腺癌病史患者的预后意义。
J Cardiothorac Surg. 2022 Jun 18;17(1):160. doi: 10.1186/s13019-022-01898-4.
10
Management of Ground-Glass Nodules: When and How to Operate?磨玻璃结节的管理:何时以及如何进行手术?
Cancers (Basel). 2022 Jan 29;14(3):715. doi: 10.3390/cancers14030715.

本文引用的文献

1
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).亚肺叶切除术与肺叶切除术治疗早期非小细胞肺癌的围手术期死亡率和发病率:一项国际、随机、III 期试验(CALGB/Alliance 140503)的事后分析。
Lancet Respir Med. 2018 Dec;6(12):915-924. doi: 10.1016/S2213-2600(18)30411-9. Epub 2018 Nov 12.
2
Long-term outcomes of stage I NSCLC (≤3 cm) patients following segmentectomy are equivalent to lobectomy under analogous extent of lymph node removal: a PSM based analysis.I期非小细胞肺癌(≤3cm)患者在进行类似范围淋巴结清扫的肺段切除术后的长期预后与肺叶切除术相当:一项基于倾向评分匹配的分析。
J Thorac Dis. 2017 Nov;9(11):4561-4573. doi: 10.21037/jtd.2017.10.129.
3
Stereotactic Body Radiation Therapy Versus Surgery for Early Lung Cancer Among US Veterans.立体定向体部放疗与手术治疗美国退伍军人早期肺癌的比较。
Ann Thorac Surg. 2018 Feb;105(2):425-431. doi: 10.1016/j.athoracsur.2017.07.048. Epub 2017 Nov 30.
4
Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.具有治愈意图的非小细胞肺癌切除术后病理淋巴结分期质量与生存的相关性研究。
JAMA Oncol. 2018 Jan 1;4(1):80-87. doi: 10.1001/jamaoncol.2017.2993.
5
Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.外周临床T1a N0期非小细胞肺癌淋巴结转移的临床预测因素
Ann Thorac Surg. 2017 Oct;104(4):1153-1158. doi: 10.1016/j.athoracsur.2017.02.074. Epub 2017 May 24.
6
The Eighth Edition Lung Cancer Stage Classification.《第八版肺癌分期分类》
Chest. 2017 Jan;151(1):193-203. doi: 10.1016/j.chest.2016.10.010. Epub 2016 Oct 22.
7
Does Lymph Node Count Influence Survival in Surgically Resected Non-Small Cell Lung Cancer?淋巴结数量对手术切除的非小细胞肺癌患者的生存率有影响吗?
Ann Thorac Surg. 2017 Jan;103(1):226-235. doi: 10.1016/j.athoracsur.2016.05.018. Epub 2016 Jul 26.
8
Nodal Upstaging During Lung Cancer Resection Is Associated With Surgical Approach.肺癌切除术中淋巴结分期上调与手术方式有关。
Ann Thorac Surg. 2016 Jan;101(1):238-44; discussion 44-5. doi: 10.1016/j.athoracsur.2015.05.136. Epub 2015 Sep 28.
9
Improving the pathologic evaluation of lung cancer resection specimens.提高肺癌切除标本的病理评估。
Transl Lung Cancer Res. 2015 Aug;4(4):432-7. doi: 10.3978/j.issn.2218-6751.2015.07.07.
10
Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base.临床I A期肺癌肺叶下切除与肺叶切除术后的生存率:来自国家癌症数据库的分析
J Thorac Oncol. 2015 Nov;10(11):1625-33. doi: 10.1097/JTO.0000000000000664.

周围型临床 N0 小细胞肺癌(≤2cm)隐匿性支气管周围 N1 淋巴结转移的发生率。

Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer.

机构信息

Department of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Icahn School of Medicine at Mount Sinai, New York, New York.

Department of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

Ann Thorac Surg. 2020 Jan;109(1):270-276. doi: 10.1016/j.athoracsur.2019.07.037. Epub 2019 Aug 31.

DOI:10.1016/j.athoracsur.2019.07.037
PMID:31479639
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6917881/
Abstract

BACKGROUND

There has been growing interest in limited resection and nonsurgical treatment for small lung cancers. We examined the pattern and rate of occult N1 nodal metastasis in patients with peripheral, small (≤2 cm), clinically node-negative non-small cell lung cancer (NSCLC).

METHODS

Patients with peripheral small (≤2 cm) NSCLC with no evidence of locally advanced or metastatic disease (clinical T1a-b N0 M0, American Joint Committee on Cancer 8th Edition Cancer Staging Manual), who were deemed eligible for lobectomy or sublobar resection, were identified from preregistration eligibility screening logs for the Alliance/Cancer and Leukemia Group B 140503 trial at our institution. Pathologic outcomes were examined in all patients undergoing anatomic resection with mediastinal and hilar lymphadenectomy.

RESULTS

Included were 58 patients treated between November 2014 and January 2017 who met the inclusion criteria: 51 underwent lobectomy, and 7 underwent segmentectomy. Mean tumor diameter on computed tomography was 1.5 cm, and mean positron emission tomography maximal standardized uptake value was 3.9. The mean consolidation-to-tumor ratio was 0.77. Occult nodal metastases in N1 stations were found in 8 of 58 patients (14%), and most of these nodes were found in interlobar or peribronchial stations (11 or 12). An additional 2 patients (3%) had occult positive N2 nodes. Overall, the false-negative rate for clinical staging was 16%.

CONCLUSIONS

Occult nodal disease was frequently identified in peripheral N1 stations (11-13) in patients with small (≤2 cm) clinical N0 NSCLC. Hilar lymphadenectomy is essential for accurate staging in the management of patients with small clinical N0 NSCLC.

摘要

背景

对于小肺癌,人们越来越关注局限性切除术和非手术治疗。我们研究了周围性、小(≤2cm)、临床淋巴结阴性非小细胞肺癌(NSCLC)患者隐匿性 N1 淋巴结转移的模式和发生率。

方法

我们从机构内联盟/癌症和白血病组 B140503 试验的预先注册资格筛选日志中确定了符合条件的患者,这些患者患有周围性小(≤2cm)NSCLC,且无局部晚期或转移性疾病的证据(临床 T1a-bN0M0,美国癌症联合委员会第 8 版癌症分期手册),被认为有资格行肺叶切除术或亚肺叶切除术。对所有接受纵隔和肺门淋巴结清扫术的解剖性切除术患者进行病理检查。

结果

纳入的 58 例患者于 2014 年 11 月至 2017 年 1 月符合纳入标准:51 例行肺叶切除术,7 例行节段切除术。CT 上平均肿瘤直径为 1.5cm,平均正电子发射断层扫描最大标准化摄取值为 3.9。平均实变与肿瘤比值为 0.77。58 例患者中有 8 例(14%)发现隐匿性 N1 淋巴结转移,这些淋巴结多位于叶间或支气管旁(11 或 12 区)。另外 2 例(3%)患者存在隐匿性阳性 N2 淋巴结。总体而言,临床分期的假阴性率为 16%。

结论

在小(≤2cm)临床 N0 NSCLC 患者中,常可在周围性 N1(11-13)区发现隐匿性淋巴结疾病。在小临床 N0 NSCLC 患者的管理中,肺门淋巴结清扫术对于准确分期至关重要。